High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Nodular Lymphocyte-Predominant Hodgkin Lymphoma

被引：33
|
作者：
Karuturi, Meghan [1 ]
Hosing, Chitra [1 ]
Fanale, Michelle [2 ]
Medeiros, L. Jeffrey [3 ]
Alousi, Amin M. [1 ]
de Lima, Marcos J. [1 ]
Qazilbash, Muzaffar H. [1 ]
Kebriaei, Partow [1 ]
Younes, Anas [2 ]
Khouri, Issa [1 ]
Andersson, Borje S. [1 ]
Champlin, Richard [1 ]
Anderlini, Paolo [1 ]
Popat, Uday [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Stem Cell Transplantat & Cellular Therapy, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2013年 / 19卷 / 06期
关键词：
Hodgkin Lymphoma; Autologous stem cell transplantation; Nodular lymphocyte predominant Hodgkin lymphoma; Relapse; Chemosensitive; STUDY-GROUP GHSG; LONG-TERM; MARROW-TRANSPLANTATION; RITUXIMAB; PHASE-2; DISEASE; TRIAL;
D O I：
10.1016/j.bbmt.2013.03.008
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Nodular lymphocyte-predominant Hodgkin lymphoma (NLPHL) is a distinct subtype of Hodgkin lymphoma that is characterized by unique clinical presentation, histological appearance, and indolent disease course. The recurrent nature of disease provides an opportunity to examine the role of stem cell transplantation in its management. We report here a single-center experience of 26 patients with relapsed NLPHL treated with high-dose chemotherapy and autologous stem cell transplantation between 1990 and 2008. With a median follow-up of 50 months (range, 2-138 months), the 5-year overall and event-free survival were 76% (SE 10%) and 69% (SE 10%), respectively. Our data suggest that high-dose chemotherapy and autologous transplantation should be considered as an option for patients with relapsed NLPHL. (C) 2013 American Society for Blood and Marrow Transplantation.
引用
收藏
页码：991 / 994
页数：4
相关论文
共 50 条
  • [31] Can Rituximab Improve the Outcome of Patients with Nodular Lymphocyte-Predominant Hodgkin's Lymphoma?
    Mocikova, Heidi
    Pytlik, Robert
    Stepankova, Pavla
    Michalka, Jozef
    Markova, Jana
    Koren, Jan
    Buresova, Lucie
    Raida, Ludek
    Kral, Zdenek
    ACTA HAEMATOLOGICA, 2015, 134 (03) : 187 - 192
  • [32] What Is the Role of Rituximab in Nodular Lymphocyte-Predominant Hodgkin Lymphoma?
    Eichenauer, Dennis A.
    Engert, Andreas
    ACTA HAEMATOLOGICA, 2015, 134 (03) : 185 - 186
  • [33] Progress in understanding the biology of nodular lymphocyte-predominant Hodgkin lymphoma
    Straus, David J.
    HAEMATOLOGICA, 2021, 106 (10) : 2538 - 2538
  • [34] Nodular lymphocyte-predominant Hodgkin lymphoma revisited: current management strategies and future perspectives
    Eichenauer, Dennis A.
    Borchmann, Peter
    LEUKEMIA & LYMPHOMA, 2024, : 830 - 837
  • [35] Nodular Lymphocyte Predominant Hodgkin Lymphoma: Biology, Diagnosis and Treatment
    Goel, Anupama
    Fan, Wen
    Patel, Amit A.
    Devabhaktuni, Madhuri
    Grossbard, Michael L.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2014, 14 (04) : 261 - 270
  • [36] Primary adrenal nodular lymphocyte-predominant Hodgkin lymphoma: A case report and review of the literature
    Wang, Jingjing
    Ma, Jin'an
    Hu, Chunhong
    Li, Daiqiang
    She, Xiaoling
    ONCOLOGY LETTERS, 2014, 8 (03) : 1147 - 1150
  • [37] High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma
    Rancea, Michaela
    Monsef, Ina
    von Tresckow, Bastian
    Engert, Andreas
    Skoetz, Nicole
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (06):
  • [38] Pediatric Nodular Lymphocyte-predominant Hodgkin Lymphoma: Treatment Recommendations of the GPOH-HD Study Group
    Mauz-Koerholz, C.
    Lange, T.
    Hasenclever, D.
    Burkhardt, B.
    Feller, A. C.
    Doerffel, W.
    Kluge, R.
    Vordermark, D.
    Koerholz, D.
    KLINISCHE PADIATRIE, 2015, 227 (6-7): : 314 - 321
  • [39] High-dose chemotherapy followed by autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma: Prognostic features and outcomes
    Engelhardt, Brian G.
    Holland, Derek W.
    Brandt, Stephen J.
    Chinratanalab, Wichai
    Goodman, Stacey A.
    Greer, John P.
    Jagasia, Madan H.
    Kassim, Adetola A.
    Morgan, David S.
    Ruffner, Katherine L.
    Schuening, Friedrich G.
    Wolff, Steven
    Bitting, Rhonda
    Sulur, Paulgun
    Stein, Richard S.
    LEUKEMIA & LYMPHOMA, 2007, 48 (09) : 1728 - 1735
  • [40] Nodular lymphocyte-predominant Hodgkin lymphoma: a unique disease deserving unique management
    Eichenauer, Dennis A.
    Engert, Andreas
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2017, : 324 - 328
12345